In the context of cancer—specifically pancreatic cancer—CDH17 (cadherin-17) has recently garnered significant global attention as both an innovative biomarker for early diagnosis and a novel therapeutic target. While this protein normally functions as a cell adhesion molecule—facilitating the binding of cells within the digestive tract, such as the stomach and intestines—it is known to be overexpressed in pancreatic cancer. Its primary clinical significance and the latest research trends are outlined below: 1. Biomarker for Early Diagnosis • High Specificity and Overexpression: CDH17 levels are markedly elevated in pancreatic cancer tissue (particularly in pancreatic ductal adenocarcinoma) compared to healthy or adjacent normal tissue. • Potential for Early Detection: By analyzing CDH17 in blood or tissue samples—or by examining specific genetic polymorphisms (haplotype SNPs) and short-isoform splicing variants—CDH17 shows promise as a new diagnostic marker for pancreatic cancer, a disease that is notoriously difficult to detect at an early stage. 2. Role in Cancer Proliferation and Metastasis (Oncogene) • Promoting Carcinogenesis and Malignancy: Recent molecular biological research has demonstrated that CDH17 functions as an "oncogene," driving the proliferation, colony formation, migration, and invasion of pancreatic cancer cells. • Impact on Cell Survival: Studies have shown that "knocking down" (suppressing) CDH17 can trigger apoptosis (programmed cell death) in pancreatic cancer cells, indicating that the protein plays a critical role in their survival. 3. Development of Next-Generation Targeted Therapies Pancreatic cancer is a challenging, hard-to-treat malignancy that often shows poor response to conventional anticancer drugs; however, the development of new therapeutic approaches specifically targeting CDH17 is currently advancing rapidly. • Development of Antibody-Drug Conjugates (ADCs): Research is underway on a new class of drugs known as "ADCs"—such as ARB1002 and LM-350—which consist of an antibody that binds specifically to CDH17, linked to a potent cytotoxic agent. These agents bind to CDH17 on the surface of cancer cells, are internalized, and destroy the targeted cancer cells from within. • FDA Orphan Drug Designation: In January 2026, the anti-CDH17 ADC candidate ARB1002 received "Orphan Drug Designation" from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer—a status that provides incentives to accelerate development—and has since advanced to Phase 1 clinical trials. • Antibody-based Drug Discovery in Japan: In Japan, research teams—including a group led by Professor Yukinari Kato at Tohoku University—have successfully developed monoclonal antibodies (such as Ca17Mab-5) that bind with high precision to intractable pancreatic cancer. These are currently being explored for applications in both diagnosis and treatment. Describe the use of CDH17 and CA19-9 as tumor markers. Additionally, discuss the use of anti-cancer drug therapies targeting CDH17 for pancreatic cancer.